Cargando…
Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate
Treatment with acetyl-CoA carboxylase inhibitors (ACCi) in nonalcoholic steatohepatitis (NASH) may increase plasma triglycerides (TGs), with variable changes in apoB concentrations. ACC is rate limiting in de novo lipogenesis and regulates fatty acid oxidation, making it an attractive therapeutic ta...
Autores principales: | Dandan, Mohamad, Han, Julia, Mann, Sabrina, Kim, Rachael, Li, Kelvin, Mohammed, Hussein, Chuang, Jen-Chieh, Zhu, Kaiyi, Billin, Andrew N., Huss, Ryan S., Chung, Chuhan, Myers, Robert P., Hellerstein, Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017426/ https://www.ncbi.nlm.nih.gov/pubmed/36737040 http://dx.doi.org/10.1016/j.jlr.2023.100339 |
Ejemplares similares
-
Analysis of apoB Concentrations Across Early Adulthood and Predictors for Rates of Change Using CARDIA Study Data
por: Wilkins, John T., et al.
Publicado: (2022) -
Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems
por: Ross, Trenton T., et al.
Publicado: (2020) -
Regulation of plasma LDL: the apoB paradigm
por: Sniderman, Allan D., et al.
Publicado: (2009) -
Acetyl-CoA Carboxylases and Diseases
por: Wang, Yu, et al.
Publicado: (2022) -
Hexacosenoyl-CoA is the most abundant very long-chain acyl-CoA in ATP binding cassette transporter D1-deficient cells
por: Hama, Kotaro, et al.
Publicado: (2020)